Navigation Links
New drug proven to tackle Type 2 Diabetes

A new drug called Rosiglitazone capable of controlling Type 2 diabetes has been given the green signal by researchers, Researchers// content that this drug is capable of reported in The Lancet ,a renounced British medical journal . Researchers content that this drug is capable of reducing Type 2 Diabetes by 60%.

The results of a 3 year long study named DREAM(for Diabetes Reduction Approaches with Medication )conducted at Royal Victoria Hospital led by endocrinologist Jean-Francois Yale have shown that in every thousand cases of “pre-diabetes” treated with Rosiglitazone,144 new cases were prevented. The drug exhibited a capability to bring down blood sugar levels to normal. This 25 million dollar study which was funded by 3 drug companies and Canadian Institutes of Health Research studied 5,000 patients recruited from over 21 countries. Canada itself has a staggering 2 million diabetics currently and is expected to cross 3 million by year 2010.

Such a breakthrough would immensely benefit individuals with a strong history of Diabetes running in the family, or were either parent or both are already known diabetics. However it has to be kept in mind that predominantly it is only a well balanced diet and regular exercise that have been proven to pay rich dividends in controlling the late onset type of diabetes, as proven in research studies. Though currently rosiglitazone is being used only as a second line treatment for diabetics, it may soon be used as a front line therapy for nearly 8% of people with high blood sugar world wide.

Rosiglitazone is still not proven in its efficacy to stall onset of Diabetes in those who fall in the high risk group or if there could be a relapse of diabetes if it is withdrawn from a patient. Nearly 2 million Canadians are diabetic. The Canadian Diabetes Association predicts that number will rise to 3 million by 2010.

It's not known yet whether the drug prevents or delays diabetes or whether i ts effects disappear once patients stop treatment.


MS
'"/>




Related medicine news :

1. TELITHROMYCIN - the proven effective new drug for cap
2. Partial-Breast Irradiation an Unproven Therapy
3. The Use of Radio Frequency Identification ( RFID) to tackle the growing menace of counterfeit drugs
4. Guidelines to tackle bird flu pandemic
5. U.S. unprepared to tackle bird flu
6. Meeting to tackle Chikungunya
7. AIDS to be tackled through Computer Games
8. Is Diabetes the Leading Cause of Kidney Failure in India
9. Diabetes and Depression often go hand-in-hand
10. Thirty minutes of work up per day reduces the risk of Diabetes
11. Diabetes on the rise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® ... no longer use or need, from clothes to couches to dressers and bicycles. Roadie ... take them to the nearest Goodwill donation center through February 28th. , “January ...
(Date:1/20/2017)... ... 20, 2017 , ... Doctor C LLC, a company based out of Arizona ... to continue the marketing and distribution of its product, The Right C. , The ... better absorption than traditional vitamin C supplements. At the trade show, Doctor C had ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, ... everyday lives, recently attended the January ECRM Trade Show in Hilton Head, SC, ... for its large range of supplements that keep the body functioning at its ...
(Date:1/20/2017)... Viejo, California (PRWEB) , ... January 20, 2017 , ... ... easy to use inside of Final Cut Pro X," said Christina Austin - CEO ... on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest tale ... each of his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, ... City, and impassioned writer. , When asked of her new book, Marjorie says, “‘The ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 ARMO BioSciences, Inc., ... data on the Company,s lead investigational immuno-oncology drug AM0010 ... by the American Society of Clinical Oncology (ASCO), taking ... CA. "AM0010 induces the ... + T cells in the blood and tumors ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
(Date:1/20/2017)... , Jan 20, 2017 Research and ... Market By Type ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c ... End-use, And Segment Forecasts, 2013 - 2024" report to their ... The ... billion by 2024 Introduction of innovative solutions on the ...
Breaking Medicine Technology: